Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
Describe the overall survival rate (OS) rate in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice.
Secondary Objectives:
To describe the following in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice:
Incidence and severity of adverse events (AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice
Full description
Originally registered as OBS17104 by Sanofi; transitioned to REGN 05Jul2023.
The recruitment period will be 36 months. Data will be collected during routine clinical visits approximately every three months while the patient is on cemiplimab treatment and then approximately every six months for up to 36 months after cemiplimab discontinuation. Patients will be followed from cemiplimab treatment initiation until death, loss to follow-up, study withdrawal, or to the end of the study period (72 months after study launch), whichever occurs first.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
300 participants in 1 patient group
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal